Patents Examined by Leigh Maier
  • Patent number: 9226939
    Abstract: The invention relates to a method of inhibiting the cytotoxic activity of extracellular histones in a subject, comprising administering an effective amount of a polyanion to the subject. In particular the invention relates to a method for the treatment of patients who are suffering from sepsis and employs polyanions to rapidly form complexes with and thus neutralize or inhibit the cytotoxic activity of extracellular histone proteins, for example, those found in the blood circulation of sepsis patients.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: January 5, 2016
    Assignee: THE AUSTRALIAN NATIONAL UNIVERSITY
    Inventors: Ross Wentworth Stephens, Christopher Richard Parish, Craig Geoffrey Freeman, Timothy John Senden
  • Patent number: 9221861
    Abstract: This invention relates to synthetic oligo- or multivalent beta-1-2-linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell-mediated immune responses.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 29, 2015
    Assignees: ABO AKADEMI UNIVERSITY, TURUN YLIOPISTO
    Inventors: Johannes Savolainen, Kaarina Mäkinen, Reko Leino, Chinmoy Mukherjee
  • Patent number: 9205104
    Abstract: The present invention aims to provide a hydrophilic modified polyrotaxane composition having excellent storage stability. The present invention relates to a hydrophilic modified polyrotaxane composition comprising: a hydrophilic modified polyrotaxane produced by modifying, with hydrophilic modifying groups, all or part of hydroxy groups on a cyclodextrin of a polyrotaxane containing the cyclodextrin, a polyethylene glycol which is included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a polyphenol antioxidant.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: December 8, 2015
    Assignees: SUMITOMO SEIKA CHEMICALS CO., LTD., ADVANCED SOFTMATERIALS INC.
    Inventors: Tomoaki Yamasaki, Shinya Okazaki, Hiroki Okazaki, Shigeki Hamamoto, Changming Zhao, Minoru Iwata, Yuki Hayashi
  • Patent number: 9173827
    Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 3, 2015
    Assignee: POLICHEM SA
    Inventor: Federico Mailland
  • Patent number: 9139718
    Abstract: Poly alpha-1,3-glucan ether compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ether compounds.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: September 22, 2015
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Jayme L Paullin, Andrea M Perticone, Rahul B Kasat, T Joseph Dennes
  • Patent number: 9132141
    Abstract: The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 15, 2015
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Stefanie Vogel, Kari Ann Shirey
  • Patent number: 9119880
    Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: September 1, 2015
    Assignee: DRP Biomedical, Inc.
    Inventor: Dale R. Peterson
  • Patent number: 9107441
    Abstract: This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fiber together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: August 18, 2015
    Assignee: INQPHARM GROUP SDN. BHD.
    Inventors: Pee Win Chong, Thomas Hafner, Istvan Puskas
  • Patent number: 9103821
    Abstract: Among other things, the present disclosure provides methods for enriching, identifying, and/or quantifying unusually modified glycans (e.g., phosphorylated glycans, sulfated glycans, and/or multi-acetylated glycans). In many embodiments, methods comprise providing a glycan preparation from which sialic acids have been released; subjecting the sialidase-treated glycan preparation to a separation technique that separates glycans based on charge-to-mass ratio; and quantifying the charged products using at least one quantification standard.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 11, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, Jennifer Lynn Murphy, Sibel Nur Gunay, Zachary Shriver, Cuihua Liu
  • Patent number: 9095597
    Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 4, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
  • Patent number: 9085525
    Abstract: Chiral salts comprising anionic cyclodextrin derivatives with particular types of non-metal cations are provided. The anionic CD derivative salts can serve as ionic liquids and can possess substantial advantages over currently commercially available ionic liquids particularly for use as chiral phase transfer catalyst, chiral reaction medium, chiral extraction medium, and/or as chiral additive to a chemical process. Methods of preparing the same are provided.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: July 21, 2015
    Inventor: Jose R Matos
  • Patent number: 9084842
    Abstract: The present invention relates to an injectable dermal filler composition that can be injected into the skin of the orbital trough of a patient without aggravating darkness around the eyes of the patient. In fact, this composition can be used to lighten such dark areas which have developed over time. The present invention more specifically discloses an injectable dermal filler composition comprising hyaluronic acid and a white colorant. The present invention further reveals a method for treating wrinkles and firming an area of skin on a human patient comprising injecting an injectable dermal filler composition comprising hyaluronic acid and a white colorant, into the area of skin on the human patient.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: July 21, 2015
    Inventor: Rania Agha
  • Patent number: 9034846
    Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: UNIVERSITE DE LIEGE
    Inventors: Didier Cataldo, Brigitte Evrard, Agnes Noel, Jean-Michel Foldart
  • Patent number: 9034847
    Abstract: A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: May 19, 2015
    Assignees: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 9024009
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 5, 2015
    Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma Corporation
    Inventors: Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • Patent number: 9018189
    Abstract: The invention relates to use of microfibrillated cellulose as an anti-inflammatory agent for treatment of skin disorders.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: April 28, 2015
    Assignee: UPM-Kymmene Oyj Corporation
    Inventors: Kaisa Herranen, Mia Lohman
  • Patent number: 9012410
    Abstract: A method of treating intrauterine inflammation in a subject associated with intrauterine bacterial infection includes administering to the subject a therapeutically effective amount of a toll-like receptor 4 antagonist. The therapeutically effective amount administered to the subject is an amount effective in reducing intrauterine inflammation in the subject.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 21, 2015
    Assignee: Case Western Reserve University
    Inventors: Yiping Han, Hongqi Liu
  • Patent number: 9006215
    Abstract: The invention relates to a pharmaceutical formulation that contains a complex of a propofol salt with a cyclodextrin. The invention makes it possible to provide propofol in a formulation that can be stored and that can be administered intravenously without problems.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: April 14, 2015
    Inventors: Norbert Roewer, Jens Broscheit
  • Patent number: 8999952
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: April 7, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Manoj Nerurkar, Vijay H. Naringrekar
  • Patent number: 9000045
    Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity. the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: April 7, 2015
    Assignee: Japan Tobacco Inc.
    Inventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto